» Articles » PMID: 38773068

In Vivo Neutralization of Coral Snake Venoms with an Oligoclonal Nanobody Mixture in a Murine Challenge Model

Abstract

Oligoclonal mixtures of broadly-neutralizing antibodies can neutralize complex compositions of similar and dissimilar antigens, making them versatile tools for the treatment of e.g., infectious diseases and animal envenomations. However, these biotherapeutics are complicated to develop due to their complex nature. In this work, we describe the application of various strategies for the discovery of cross-neutralizing nanobodies against key toxins in coral snake venoms using phage display technology. We prepare two oligoclonal mixtures of nanobodies and demonstrate their ability to neutralize the lethality induced by two North American coral snake venoms in mice, while individual nanobodies fail to do so. We thus show that an oligoclonal mixture of nanobodies can neutralize the lethality of venoms where the clinical syndrome is caused by more than one toxin family in a murine challenge model. The approaches described may find utility for the development of advanced biotherapeutics against snakebite envenomation and other pathologies where multi-epitope targeting is beneficial.

Citing Articles

Target product profiles for pan-Africa recombinant antivenoms against neurotoxic or hemotoxic and cytotoxic snakebite envenoming.

Laustsen A, Benard-Valle M, Habib A, Casewell N, Abouyannis M, Lalloo D PLoS Negl Trop Dis. 2025; 19(1):e0012833.

PMID: 39854596 PMC: 11759373. DOI: 10.1371/journal.pntd.0012833.


First Look at the Venoms of Two Snakes: Differences in Yield, Proteomic Profiles, and Immunorecognition by Commercial Antivenoms.

Li X, Zhang Y, Qian X, Zhao H, Lu H, Gao J Toxins (Basel). 2025; 17(1).

PMID: 39852972 PMC: 11769021. DOI: 10.3390/toxins17010019.


Microbes Saving Lives and Reducing Suffering.

Timmis K, Karahan Z, Ramos J, Koren O, Perez-Cobas A, Steward K Microb Biotechnol. 2025; 18(1):e70068.

PMID: 39844583 PMC: 11754571. DOI: 10.1111/1751-7915.70068.


Next-generation snakebite therapies could reduce death toll.

Willyard C Nature. 2024; .

PMID: 39572669 DOI: 10.1038/d41586-024-03818-z.


Neutralizing Nanobodies against Venoms from Species Captured in North Africa.

Mejri H, Mokrani R, Ksouri A, Seddik M, Awad N, Ayme G Toxins (Basel). 2024; 16(9).

PMID: 39330851 PMC: 11435604. DOI: 10.3390/toxins16090393.


References
1.
Yin M, Izadi M, Tenglin K, Viennet T, Zhai L, Zheng G . Evolution of nanobodies specific for BCL11A. Proc Natl Acad Sci U S A. 2023; 120(3):e2218959120. PMC: 9933118. DOI: 10.1073/pnas.2218959120. View

2.
Gutierrez J, Solano G, Pla D, Herrera M, Segura A, Vargas M . Preclinical Evaluation of the Efficacy of Antivenoms for Snakebite Envenoming: State-of-the-Art and Challenges Ahead. Toxins (Basel). 2017; 9(5). PMC: 5450711. DOI: 10.3390/toxins9050163. View

3.
Benard-Valle M, Neri-Castro E, Elizalde-Morales N, Olvera-Rodriguez A, Strickland J, Acosta G . Protein composition and biochemical characterization of venom from Sonoran Coral Snakes (Micruroides euryxanthus). Biochimie. 2021; 182:206-216. DOI: 10.1016/j.biochi.2021.01.003. View

4.
OBrien M, Forleo-Neto E, Sarkar N, Isa F, Hou P, Chan K . Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial. JAMA. 2022; 327(5):432-441. PMC: 8808333. DOI: 10.1001/jama.2021.24939. View

5.
Burton D, Poignard P, Stanfield R, Wilson I . Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science. 2012; 337(6091):183-6. PMC: 3600854. DOI: 10.1126/science.1225416. View